Navigation Links
Big Pharma to Big Biopharma: Frost & Sullivan Examines the Latest M&A Trends and Opportunities

London, July 20 /PRNewswire/ -- There has been a recent upsurge in Merger & Acquisition (M&A) activities in the pharmaceutical and biotechnology space. While the economic downturn and related credit crunch has had an impact, this alone cannot account for the recent M&A mania, which has including four mega M&As in the first half of 2009.


"The real intention behind these mergers remains a question, as past mergers have not yielded substantial value addition in terms of R&D productivity," says Frost & Sullivan Senior Research Analyst Ranjith Gopinathan.

To look at these Mergers & Acquisitions in the Pharmaceutical and Biotechnology industry, the Healthcare Group at Frost & Sullivan will be hosting a complimentary Analyst Briefing Presentation on Tuesday, 28th July 2009, at 2 p.m. BST/ 1 p.m. GMT.

Highlights of this briefing will include an analysis of the factors contributing to the increasing consolidation in the market, the impact of the economic downturn, as well as funding sources for biotech companies. The briefing will also look at key restraints for M&A activities in the pharma-biotech industry and provide a future M&A outlook. The discussion will benefit venture capitalists, investment banks, pharma and biotech companies as well as academic institutions.

"The global downturn's detrimental impact on funding availability coupled with an average 30 per cent decline in the value of biotech firms, means that outright acquisitions rather than complex licensing deals are an attractive proposition," concludes Gopinathan.

To participate in this briefing, please email Patrick Cairns at with the following information: your full name, company name, title, telephone number, e-mail address, city, state, and country. Upon receipt of the above information, a registration link will be emailed to you.

About Frost & Sullivan:

Frost & Sullivan, the Growth Partnership Company, partners with clients to accelerate their growth. The company's TEAM Research, Growth Consulting and Growth Team Membership empower clients to create a growth-focused culture that generates, evaluates and implements effective growth strategies. Frost & Sullivan employs over 45 years of experience in partnering with Global 1000 companies, emerging businesses and the investment community from more than 35 offices on six continents. For more information about Frost & Sullivan's Growth Partnerships, visit

    Patrick Cairns
    Corporate Communications
    P: +27 18 468 2315
    M: +27 83 258 4219

SOURCE Frost & Sullivan
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. VIA Pharmaceuticals Receives Anticipated Notice From NASDAQ
2. Angiotech Pharmaceuticals announces FDA approval of TAXUS(R) Liberte(R) Long Stent
3. Pharmacyclics Announces Subscription Price for Rights Offering
4. EnVivo Pharmaceuticals Announces Results and Successful Completion of EVP-6124 Phase Ib/IIa Trial at the International Conference on Alzheimers Disease
5. Simcere Pharmaceutical Group Notice of Annual General Meeting
6. Amylin Pharmaceuticals to Webcast Second Quarter Results
7. EnVivo Pharmaceuticals Announces Reversal of Cognitive Deficits in Alzheimers Disease Transgenic Mouse Model With Gamma-Secretase Modulator
8. Santaris Pharma - Interim Report for the Period 1 January to 30 June 2009
9. ClearTrial Selected to Lead Executive Panel from Pharmaceutical and Service Provider Companies at ExL Conference
10. Inspiration Biopharmaceuticals Presents Safety Data on IB1001, a Novel Recombinant Factor IX for the Treatment of Hemophilia at the International Society on Thrombosis and Haemostasis (ISTH) Annual Meeting
11. ParagonRx Creates New Website Featuring REMS Help Center for Pharma
Post Your Comments:
(Date:11/27/2015)... /PRNewswire/--  Mallinckrodt plc (NYSE: MNK ), a ... closed the sale of its global contrast media and ... in a transaction valued at approximately $270 million. The ... total of approximately 1,000 employees spread across the globe, ... area. This entire workforce and the manufacturing ...
(Date:11/25/2015)... PUNE, India , November 26, 2015 /PRNewswire/ ... The Global Biobanking Market 2016 - 2020 ... biobanks by maintaining integrity and quality in long-term ... and enabling long-term cost-effectiveness. Automation minimizes manual errors ... improves the technical efficiency. Further, it plays a ...
(Date:11/25/2015)... SAN DIEGO , Nov. 25, 2015  Neurocrine ... Kevin Gorman , President and CEO of Neurocrine ... Jaffray Healthcare Conference in New York ... encouraged to visit the website approximately 5 minutes prior ... software.  A replay of the presentation will be available ...
(Date:11/25/2015)... ... November 25, 2015 , ... ... were featured on AngelList early in their initial angel funding process. Now, they ... for individuals looking to make early stage investments in the microbiome space. ...
Breaking Biology Technology:
(Date:11/11/2015)...   MedNet Solutions , an innovative SaaS-based eClinical technology ... pleased to announce that it will be a Sponsor of ... to be held November 17-19 in Hamburg ... of iMedNet , MedNet,s easy-to-use, proven and ... has been able to deliver time and cost savings of ...
(Date:11/9/2015)... , Nov. 09, 2015 ... the addition of the "Global Law ... their offering. --> ) ... "Global Law Enforcement Biometrics Market 2015-2019" ... Research and Markets ( ) has ...
(Date:11/2/2015)...  SRI International has been awarded a contract of ... to the National Cancer Institute (NCI) PREVENT Cancer Program ... modern testing and support facilities, and analytical instrumentation to ... studies to evaluate potential cancer prevention drugs. ... Drug Development Program is an NCI-supported pipeline to bring ...
Breaking Biology News(10 mins):